Overview: OTC Mutation TestIntroduction: The OTC Mutation Test tests for OTC gene mutations to diagnose ornithine transcarbamylase deficiency, causing ammonia buildup or neurological issues, aiding in genetic diagnosis. Affecting 1 in 50,000 people, OTC deficiency poses diagnostic challenges due to variable presentation. Following 2023 National Organization for Rare Disorders (NORD) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, genetic counseling, and improving outcomes in metabolism.
Other Names: OTC Gene Test, OTC Deficiency Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: OTC mutation testing began in the 1990s with research by Brusilow, who identified the gene. PCR/sequencing advancements by Illumina improved detection, surpassing earlier linkage analysis.
Purpose: Detects OTC mutations to diagnose OTC deficiency, guides ammonia-lowering therapy, and evaluates patients with neurological issues, aiming to manage ammonia.
Test Parameters: OTC mutation status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of metabolic issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological issues or ammonia buildup. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., coma), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation confirms OTC deficiency, guiding therapy. Early treatment might prevent crises, while untreated cases lead to death. Normal results may require other tests.
Specialist Consultation: Consult a metabolic specialist or genetic counselor for interpretation.
Additional Supporting Tests: Ammonia levels, amino acid profile, or genetic panel to confirm diagnosis.
Test Limitations: Specific to OTC; correlation with clinical status needed. False negatives possible with other mutations.
References: NORD Guidelines, 2023; Journal of Pediatrics, Brusilow SW, 2022.
